1.95

1.04% 0.02

After Hours: 1.91 -0.04 -2.05%

Black Diamond Therapeutics Inc (BDTX)

Overview News Price History Option Chain Financials Discussions Forecast

Black Diamond Therapeutics Inc stock is traded at $1.95, with a volume of 842.41K. It is up +1.04% in the last 24 hours and up +43.38% over the past month. Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.

Previous Close:

$1.93

Open:

$1.93

24h Volume:

842.41K

Relative Volume:

0.27

Market Cap:

$110.88M

Revenue:

Net Income/Loss:

$-82.44M

P/E Ratio:

-1.0372

EPS:

-1.88

Net Cash Flow:

$-66.75M

1W Performance:

+18.90%

1M Performance:

+43.38%

6M Performance:

-25.57%

1Y Performance:

-62.79%

1-Day Range:

$1.875

$1.99

1-Week Range:

$1.68

$1.99

52-Week Range:

$1.195

$6.75

Black Diamond Therapeutics Inc Stock (BDTX) Company Profile

Name

Black Diamond Therapeutics Inc

Sector

Healthcare (1170)

Industry

Biotechnology (671)

Phone

617-417-5868

Address

ONE MAIN STREET, 14TH FLOOR, CAMBRIDGE, MA

Employee

Twitter

Next Earnings Date

2024-11-04

Latest SEC Filings

BDTX's Discussions on Twitter

Compare BDTX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BDTX Black Diamond Therapeutics Inc	1.95	92.95M	0	-82.44M	-66.75M	-1.88
ONC Beigene Ltd Adr	228.38	25.07B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	438.65	109.14B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.27	36.39M	0	0	0	0.00
REGN Regeneron Pharmaceuticals Inc	594.32	56.98B	14.09B	4.50B	2.96B	39.28
VRNA Verona Pharma Plc Adr	71.31	5.39B	0	-153.72M	-103.81M	-2.00

Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-31-24	Initiated	Raymond James	Outperform
Jul-14-23	Initiated	Piper Sandler	Overweight
Jun-30-23	Upgrade	Stifel	Hold → Buy
Jun-28-23	Upgrade	H.C. Wainwright	Neutral → Buy
Jun-27-23	Upgrade	Wedbush	Neutral → Outperform
Mar-29-22	Downgrade	Wedbush	Outperform → Neutral
Mar-22-22	Downgrade	H.C. Wainwright	Buy → Neutral
Sep-30-21	Initiated	Stifel	Hold
Jan-07-21	Initiated	Wedbush	Outperform
Nov-24-20	Initiated	Berenberg	Buy
May-04-20	Initiated	H.C. Wainwright	Buy
Feb-24-20	Initiated	Canaccord Genuity	Buy
Feb-24-20	Initiated	Cowen	Outperform
Feb-24-20	Initiated	JP Morgan	Overweight
Feb-24-20	Initiated	Jefferies	Buy

View All

Black Diamond Therapeutics Inc Stock (BDTX) Latest News

02:12 AM

Wedbush Issues Optimistic Estimate for BDTX Earnings - Defense World

02:12 AM

May 15, 2025

Raymond James Financial Inc. Makes New Investment in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World

May 15, 2025

May 14, 2025

Stifel Financial Corp Raises Stock Position in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World

May 14, 2025

Wells Fargo & Company MN Buys 5,932 Shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World

May 14, 2025

May 13, 2025